Aspirin Matches Rivaroxaban for Joint Surgery Clots

Adults having hip or knee replacement saw similar bleeding risk with low-dose aspirin as with a prescription blood thinner.

Updated on Nov. 4, 2026 in Stroke

Bold vector editorial illustration of two plain tablets, one round and one oval, side by side on a pale surface, suggesting equal footing between two clot-prevention options.
A clinical trial published in The New England Journal of Medicine found low-dose aspirin prevented blood clots after hip and knee replacement about as well as the prescription drug rivaroxaban. AI Illustration. Upload story photo >

Aspirin was found non-inferior to rivaroxaban followed by aspirin for preventing blood clots after hip or knee replacement surgery, according to results of the EPCAT III trial published in The New England Journal of Medicine. The findings apply to patients undergoing arthroplasty who need postoperative clot prevention.

Why it matters

Blood clots in the legs and lungs are a recognized risk after joint replacement, and the choice of preventive drug affects both protection and bleeding risk. Evidence that a low-dose aspirin regimen performs comparably to a prescription anticoagulant gives clinicians and patients another option to weigh.

This randomised trial enrolled 5,429 patients with a mean age of 66.5 years who underwent hip or knee arthroplasty. Its extension study compared once-daily 81mg aspirin against 10mg rivaroxaban, with no clinically relevant difference in bleeding events reported, though absolute clot-event rates were not described in the source.

The players

EPCAT III trial

A randomised trial studying extended low-dose aspirin for blood clot prevention after hip and knee replacement, and an extension of the EPCAT II study.

The New England Journal of Medicine

A leading peer-reviewed medical journal that published the EPCAT III results.

The details

Patients were randomised to receive once-daily thromboprophylaxis with either 81mg aspirin or 10mg rivaroxaban for five days after surgery. Rivaroxaban recipients then took 81mg aspirin daily for the remaining prophylaxis period, while aspirin patients continued for nine additional days after knee replacement or 30 days after hip replacement. The regimen was assessed across a 90-day postoperative window.

Timeline

  1. Five days postoperatively: initial once-daily thromboprophylaxis period.

  2. Nine additional days: aspirin continuation after knee arthroplasty.

  3. 30 days: aspirin continuation after hip arthroplasty.

  4. 90-day postoperative period: window in which clot prevention was assessed.

Health Landscape

EPCAT III builds on the EPCAT II trial, which found extended low-dose aspirin non-inferior to continued rivaroxaban after joint replacement. Together the two studies add to the evidence base on whether a low-cost, widely available drug can serve as an alternative to prescription anticoagulants for postoperative clot prevention.

If you are facing a hip or knee replacement, the postoperative clot-prevention plan is a worthwhile topic to raise with your surgeon, since both aspirin and prescription anticoagulants are options the study compared. Population-level results suggest bleeding risk did not differ meaningfully between the two approaches, but the right choice depends on your own history, so discuss it with your physician before the procedure.

The takeaway

Aspirin performed comparably to rivaroxaban for clot prevention after joint replacement in this trial, a finding worth knowing if you are preparing for surgery. Ask your surgeon which postoperative prevention plan fits your health profile.

Further reading

For related context on clot-related risks, explore our Stroke coverage.

Source note: This article includes information reported by AusDoc.